March 2010 April 2010 May 2010 June 2010 July 2010
August 2010
September 2010 October 2010
November 2010
December 2010
January 2011
February 2011 March 2011 April 2011 May 2011 June 2011 July 2011 August 2011 September 2011 October 2011 November 2011 December 2011 January 2012 February 2012 March 2012 April 2012 May 2012 June 2012 July 2012 August 2012 September 2012 October 2012 November 2012 December 2012 January 2013 February 2013 March 2013 April 2013 May 2013 June 2013 July 2013 August 2013 September 2013 October 2013 November 2013 December 2013 January 2014 February 2014 March 2014 April 2014 May 2014 June 2014 July 2014 August 2014 September 2014 October 2014 November 2014 December 2014 January 2015 February 2015 March 2015 April 2015 May 2015 June 2015 July 2015 August 2015 September 2015 October 2015 November 2015 December 2015 January 2016 February 2016 March 2016 April 2016 May 2016 June 2016 July 2016 August 2016 September 2016 October 2016 November 2016 December 2016 January 2017 February 2017 March 2017 April 2017 May 2017 June 2017 July 2017 August 2017 September 2017 October 2017 November 2017 December 2017 January 2018 February 2018 March 2018 April 2018 May 2018 June 2018 July 2018 August 2018 September 2018 October 2018 November 2018 December 2018 January 2019 February 2019 March 2019 April 2019 May 2019 June 2019 July 2019 August 2019 September 2019 October 2019 November 2019 December 2019 January 2020 February 2020 March 2020 April 2020 May 2020 June 2020 July 2020 August 2020 September 2020 October 2020 November 2020 December 2020 January 2021 February 2021 March 2021 April 2021 May 2021 June 2021 July 2021 August 2021 September 2021 October 2021 November 2021 December 2021 January 2022 February 2022 March 2022 April 2022 May 2022 June 2022 July 2022 August 2022 September 2022 October 2022 November 2022 December 2022 January 2023 February 2023 March 2023 April 2023 May 2023 June 2023 July 2023 August 2023 September 2023 October 2023 November 2023 December 2023 January 2024 February 2024 March 2024
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
30
31
News Every Day |

US risks falling behind foreign competitors on next generation vaccines. Congress must act now

US risks falling behind foreign competitors on next generation vaccines. Congress must act now

As the United States heads into its third pandemic winter, White House COVID Coordinator Ashish Jha says regarding tools: "the medicine cabinet has actually shrunk." While the rapid development of mRNA vaccines in 2020 and rollout in 2021 put the United States firmly on the map as the global leader in COVID-19 pharmaceutical innovation and global vaccine provision, this has not kept pace with continued vaccine innovation. While technology developed and proven here in the us is now used in 112 countries worldwide, there is now a risk this lead is being lost. In order not to squander that lead and the geopolitical advantages it confers, the United States needs to keep innovating. Congress must act now to fund the development of next generation vaccines.  

Today, as the virus mutates to evade the protection once almost assured by hallmark mRNA vaccines and treatments, the race to develop next generation vaccines—and the downstream impacts of that technology—is quietly underway. Technologies such as mucosal entry, inhaled vaccines, or variant-proof pan-coronavirus vaccines hold promise for blocking transmission and getting ahead of continuously mutating variants. But despite decades of basic research funding, the U.S. risks falling behind foreign competitors in bringing these new technologies to market.  

Take, for example, the case of the nasal vaccine developed by scientists at the Washington University in St. Louis. Based on early promising studies, Indian vaccine maker Bharat Biotech licensed Washington University’s nasal vaccine technology in 2020, started clinical trials in India in March of 2021, and completed its phase 3 trial in August of 2022, thus allowing to India to take the global-lead to approve the vaccine this September. In October 2022, the same Washington University’s adenovirus-vector-based mucosal vaccine technology was licensed by Pennsylvania-based Ocugen—however, to make the technology available in the United States, clinical trials in the U.S. are critically needed. The United States risks, as the New York Times put it, “creating a scenario in which Americans would have to travel abroad for the latest in American vaccine technology” if the status quo persists. 

Meanwhile, China aims to leapfrog ahead and recently began to roll out a Chinese-developed inhaled mucosal vaccine to its population based on similar technology on a large scale. While no head-to-head comparisons with Pfizer and Moderna vaccines have been done, China is already nearing completion of a large Phase 3 trial and has begun a Phase 4 trial to evaluate post-market clinical impact of its inhaled vaccine—in other words, China may be pulling ahead. In contrast, while the U.S. has the WU mucosal vaccine ready to test in the U.S. and able to enter human trials quickly—no trials are ready due to complete absence of new congressionally-approved funding.  

A U.S. trial studying the effectiveness of a mucosal vaccine’s ability to induce protective immunity at the point of entry of the virus, thus reducing infection and transmission, needs to be urgently conducted—but this is lacking in critical support. A series of new research articles undergirding the potential superiority of inhaled vaccine, here and here, showed that an aerosolized (inhaled) vaccine delivered via a nebulized form not only produced a greater antibody response than the intramuscular version, but also raised antibody levels over 9-fold, and did so at a much lower dose – important for lowering potential side events. More importantly, as Akiko Iwasaki and Eric Topol wrote in Science, inhaled vaccines also have the potential to induce a broader ‘mucosal immunity’, which could better defend against breakthrough infection, not just severe disease. This is why we need a mucosal vaccine trial funded soon. 

Basic research across a range of new technologies remains strong in the U.S., but the push to commercialize these innovations is lagging. In October, researchers funded in part by US taxpayer dollars through NIH and led by Professor Iwasaki at Yale published results of a new approach to mucosal immunity called ‘prime and spike’ in Science that shows promise in reducing transmission.  NIH-funded researchers in Texas are also part of a broader research push to develop variant-proof vaccines with encouraging results in animal models published in Science in September. 

“The United States and democratic nations have an inherent advantage – a robust clinical trial process with transparency that can garner global credibility that autocratic nations like China and Russia could only dream of,” says Lindsay Gorman, head of Technology and Geopolitics at the Alliance for Securing Democracy at the German Marshall Fund and a former White House advisor, “But only if we play the cards we have by aggressively running trials and rapidly producing public results – like we did with the first generation of vaccines in 2020.  

“The US and China have both identified biotechnology as a strategic priority area for national competitiveness,” she says. Yet the next generation of mucosal-administered COVID vaccines have stalled in the United States.  By putting all our eggs solely into the basket of first-generation COVID vaccines, the U.S. risks falling behind foreign rivals eager to lead in Gen 2.0. There’s still opportunity for the United States to come out with the 2.0 global winner. But in the face of foreign competition, it will require investing in, expediting, and rigorously testing next generation technologies. 

As Congress takes up funding proposals in the lame-duck session and early next year, the White House has requested $5 billion for new vaccines and treatments. Funding that is specifically earmarked for next generation vaccine development is an urgent priority both for the moment and for long-term US biotechnology competitiveness. Such funds should go to BARDA, but also DARPA, which was instrumental to the development of mRNA technology as well as monoclonal antibody treatments. In this next generation ‘biotech space race,’ the urgency of now to not lose our lead or let China leapfrog the U.S. in vaccine technology for COVID, flu, and future pandemic viruses is critical.  

Absent dedicated congressional funding, and funding deployed very soon, the next generation of COVID vaccines to hopefully end the pandemic once and for all, may instead come from overseas and controlled by overseas countries and corporations – even if based on U.S.-origin technology. Therefore, the U.S. risks, as the New York Times put it, “creating a scenario in which Americans would have to travel abroad for the latest in American vaccine technology” if the current funding lag continues. 

We cannot rest on our early achievements of a successful first-generation mRNA vaccines, that have been hailed in the first two years of the pandemic as a triumph of decades of US innovation, yet, only to see our gains slip away in year three of the pandemic as variants evade our ability to curb their spread, and thus, more resistant variants. We are only at halftime of the pandemic—let's not blow our biotech lead by resting on our laurels. 

Eric Feigl-Ding is an epidemiologist and health economist, and the Chief of the COVID Task Force at the World Health Network, and faculty at the New England Complex Systems Institute. 

News Every Day

I was diagnosed with cancer aged 39… you are never too rich, too famous or too young, says Dr Philippa Kaye

Top 10 Love Affair Movies of the 2000s and 2010s

The 10 Intense New Action Movies on Netflix That Left Me on the Edge of My Seat!

Top 5 Websites to Watch FREE Movies - TV Shows (No Sign up!)

I was diagnosed with cancer aged 39… you are never too rich, too famous or too young, says Dr Philippa Kaye

Ria.city






Read also

Operators engage Google on data privacy

Future Lawyer Kim Kardashian Sued for Alleged Fake Furniture

Biden’s $25 Million NYC Fundraiser Disrupted by Pro-Palestine Protestors: ‘You Are Funding Genocide’

News, articles, comments, with a minute-by-minute update, now on Today24.pro

News Every Day

Top 10 Emmanuelle Seigner Movies

Today24.pro — latest news 24/7. You can add your news instantly now — here


News Every Day

Top 5 Websites to Watch FREE Movies - TV Shows (No Sign up!)



Sports today


Новости тенниса
WTA

Россиянка покинула WTA-1000 из-за проблем со здоровьем



Спорт в России и мире
Москва

Блиц-матч по шахматам между двумя командами провели в павильоне «Спорт для каждого»



All sports news today





Sports in Russia today

Москва

Блиц-матч по шахматам между двумя командами провели в павильоне «Спорт для каждого»


Новости России

Game News

Красочное приключение Lona: Realm Of Colors перенесли на смартфоны


Russian.city


Москва

Энергетические поля компенсируют растущие потребности в электроэнергии


Губернаторы России
Чемпионат

Чемпионат по зимнему плаванию пройдет в Пскове


Шапки женские вязаные на Wildberries, 2024 — новый цвет от 392 руб. (модель 466)

Начало апреля в Татарстане будет теплым

Собянин: В Москве выберут лучший реализованный проект в области строительства

Metaratings: "Спартак" может уволить Абаскаля по ходу сезона, клуб ищет тренера


Певица Любовь Успенская назвала россиян своей семьей

Концерт благотворительного фонда Владимира Спивакова прошел в Солнечногорске

Скульптура Сергея Рахманинова украсит музыкальную школу в Кисловодске

Певица Ирина Понаровская перенесла концерт в Москве


Александрова обыграла первую ракетку мира на турнире WTA

Теннисистка Александрова оказалась сильнее полячки Швентек на турнире WTA в США

Янник Синнер поделился впечатлениями от общения с игроками сборной Италии по футболу

Хачанов: хочу вернуться в топ-10 ATP



Пассажир рейса Москва — Пермь попал в реанимацию

Архитектурные доминанты округов Москвы

Шапки женские вязаные на Wildberries, 2024 — новый цвет от 392 руб. (модель 466)

Перенос дат II этапа культурного проекта «Классика: история и современность» в Дмитрове


Всем по местам: в России назвали топ благополучных регионов

Выставка военных фотокорреспондентов и художника Росгвардии «СВОй VZгляд» открылась в Москве

Фильм Джонни Деппа о Модильяни покажут в России

В хоккейном ЦСКА сменился главный тренер


Примерно 21% всех НПЗ в мире находятся под угрозой закрытия

Есть народная мудрость: Доверяй, но проверяй!

Аэропорт Якутск с 31 марта перейдет на весенне-летнее расписание

За встречающих и провожающих в аэропортах России началась борьба



Путин в России и мире






Персональные новости Russian.city
Джиган

Джиган раскрыл свой вес и описал причину похудения словами «надоело быть жирным»



News Every Day

I was diagnosed with cancer aged 39… you are never too rich, too famous or too young, says Dr Philippa Kaye




Friends of Today24

Музыкальные новости

Персональные новости